The battle between AstraZeneca/Merck & Co’s Lynparza and GlaxoSmithKline’s Zejula now rages on in the immunotherapy world. In April, the FDA approved Zejula for maintenance therapy in advanced ovarian, fallopian tube, or primary peritoneal cancer patients in complete or partial response to frontline platinum-based chemotherapy.

The FDA already granted priority review designation in January 2020 to a supplemental new drug application (sNDA) for Lynparza in this same setting. Read more here.